2024年9月26日 · A conversation with two Sanofi physicians on a quest to bring new first and best-in-class medicines to people suffering from atopic dermatitis and other debilitating skin conditions caused by chronic inflammation.

We have a first in class treatment and a robust pipeline of potential new medicines for a variety of chronic inflammatory diseases. We currently have a marketed product with several indications in dermatology, respiratory and gastroenterology, and being evaluated for additional conditions, including ones with underlying type 2 inflammation.

Discover Sanofi's advancements in immunology. As a pioneer in Type 2 Inflammation, we improve lives by targeting immune diseases with cutting-edge science. Sanofi has a robust pipeline of potential new medicines for chronic dermatologic, …

2015年5月26日 · Dupixent is a fully-human monoclonal antibody that inhibits the signalling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins, and is not an immunosuppressant.

2024年3月11日 · Details : KY1005 (amlitelimab) is a non-T cell depleting antibody blocking OX40-Ligand, potential first-in-class for moderate-to-severe atopic dermatitis. Sanofi is a pioneer in …

Wir forschen intensiv auf dem Gebiet verschiedener Hauterkrankungen, zum Beispiel zur Neurodermitis, chronisch spontanen Nesselsucht und zur Prurigo nodularis. Auch wenn es auf den ersten Blick so aussieht, sind diese Erkrankungen keine oberflächliche Hauterkrankung, sondern eine chronische Entzündung, die unter der Haut entsteht.

We, at Sanofi, are there beside people in need, as a health journey partner. +100,000 employees, representing 142 nationalities (December 2020), 90 countries where Sanofi is present, providing healthcare solutions in 170 countries, 69 manufacturing sites in 32 countries, 21 Research and Development sites comprising medicines, clinical research ...

Dermasphere, an innovative educational program designed to illuminate the complexities of urticaria, powered by the expertise of the American Academy of Dermatology (AAD). Dermasphere offers a comprehensive exploration of this condition through engaging case studies and insightful short videos.

2025年2月10日 · Esplora trattamenti innovativi e consigli pratici sulla dermatite atopica su Campus Sanofi Italia, la tua risorsa online affidabile per i professionisti della salute interessati a questa condizione dermatologica.

2024年1月16日 · Dupixent has been used to treat hundreds of thousands of patients with moderate-to-severe atopic dermatitis around the world since its initial U.S. approval in 2017, and we are pleased that Dupixent is now the first biologic with data in the label supporting its use in this particularly challenging subset of the disease.” LIBERTY-AD-HAFT.